BLA 125486 · Genentech
Gazyva
Obinutuzumab · Injection · CD20-directed Cytolytic Antibody
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Nov 1, 2013
Approved uses
10
Original approval plus efficacy supplements
Registered trials
351
48 Phase 3, 94 recruiting
FAERS reports
16,929
14,235 serious, 2,206 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY Hepatitis B Virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients receiving CD20-directed cytolytic antibodies, including GAZYVA. Screen all patients for HBV infection before treatment initiation. Monitor HBV-positive patients during and after treatment with GAZYVA. Discontinue GAZYVA and concomitant medications in the event of HBV reactivation [see Warnings and Precautions (5.1) ] . Progressive Multifocal Leukoencephalopathy (PML) including fatal PML, can occur in patients receiving GAZYVA [see Warnings and Precautions (5.2) ] . WARNING: HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY See full prescribing information for complete boxed warning. Hepatitis B Virus (HBV) reactivation, in some cases...
What it is approved for
From the label in effect Oct 1, 2026.
GAZYVA is a CD20-directed cytolytic antibody indicated: in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL). ( 1.1 , 14 ) in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma (FL)who relapsed after, or are refractory to, a rituximab-containing regimen. ( 1.2 , 14 ) in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma. ( 1.2 , 14 ) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy ( 1.3 , 14 ) to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission. ( 1.4 , 14 ) 1.1 Chronic Lymphocytic Leukemia (CLL) GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia. 1.2 Follicular Lymphoma (FL) GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen . GAZYVA, in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, is indicated for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma . 1.3 Lupus Nephritis (LN) GAZYVA is indicated for the treatment of adult patients with active lupus nephritis who are receiving standard...
Mechanism: Obinutuzumab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes. Upon binding to CD20, obinutuzumab mediates B-cell lysis through (1) engagement of immune effector cells, (2) by directly activating intracellular death signaling pathways (direct cell death), and/or (3) activation of the complement cascade. The immune effector cell mechanisms include antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis. As an antibody with reduced fucose content, obinutuzumab induces greater ADCC activity than...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 13, 2026 Supplement 44 · Efficacy · priority review LabelLetter
- Sep 25, 2026 Supplement 43 · Efficacy · priority review OrphanLetterLabel
- Oct 17, 2025 Supplement 38 · Efficacy LabelLetter
- Oct 17, 2025 Supplement 37 · Efficacy Breakthrough therapyLabelLetterLetter
- Feb 14, 2022 Supplement 29 · Efficacy OrphanLetterLabel
- Mar 27, 2020 Supplement 25 · Efficacy · priority review OrphanLetterLabel
- Nov 16, 2017 Supplement 17 · Efficacy · priority review OrphanLabelLetter
- Feb 26, 2016 Supplement 13 · Efficacy · priority review OrphanLabelLetter
- Dec 24, 2014 Supplement 9 · Efficacy OrphanLetter
- Nov 1, 2013 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanOtherLabelReview
1 products under this application
- GAZYVA · OBINUTUZUMAB 1000MG/40ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Obinutuzumab" as an intervention, any sponsor and status, largest first.
- A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)Pivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01287741 · 1,418 participants · Start Jul 26, 2011 · Primary completion Apr 29, 2016
Drug: Rituximab; Obinutuzumab and 4 more · For: Diffuse Large B-Cell Lymphoma
Sites: Birmingham, Alabama; Chandler, Arizona; Tucson, Arizona · 235 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01332968 · 1,401 participants · Start Jul 6, 2011 · Primary completion Feb 1, 2016
Drug: Obinutuzumab; Cyclophosphamide and 5 more · For: Non-Hodgkin's Lymphoma
Sites: Springdale, Arkansas; Irvine, California; Post Falls, Idaho · 183 sites in all
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaPivotal-lookingActive, not recruiting
GenmabIndustry
NCT06191744 · 1,095 participants · Start Feb 5, 2024 · Primary completion Nov 2037
Drug: Epcoritamab; Prednisone and 7 more · For: Follicular Lymphoma (FL)
Sites: Fresno, California; San Diego, California; Santa Barbara, California · 266 sites in all
- Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLPivotal-lookingActive, not recruiting
Acerta Pharma BVAstraZeneca (AZN)
NCT03836261 · 984 participants · Start Feb 25, 2019 · Primary completion Apr 30, 2027
Drug: Acalabrutinib; Venetoclax and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Los Angeles, California; Redondo Beach, California; Fort Wayne, Indiana · 169 sites in all
- A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic LeukemiaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01905943 · 979 participants · Start Nov 4, 2013 · Primary completion Dec 29, 2016
Drug: Bendamustine; Chlorambucil and 3 more · For: Chronic Lymphocytic Leukemia
Sites: Santa Fe, Argentina; Brussels, Belgium; Hasselt, Belgium · 174 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03075696 · 940 participants (planned) · Start Feb 21, 2017 · Primary completion Mar 30, 2029
Drug: Glofitamab; Obinutuzumab and 1 more · For: Non-Hodgkin's Lymphoma
Sites: Ann Arbor, Michigan; St Louis, Missouri; New York, New York · 34 sites in all
German CLL Study GroupAcademic, hospital or other
NCT02950051 · 926 participants · Start Dec 13, 2016 · Primary completion Feb 29, 2024
Drug: Fludarabine; Cyclophosphamide and 5 more · For: Chronic Lymphocytic Leukemia
Sites: Vienna, Austria; Antwerp, Belgium; Bruges, Belgium · 161 sites in all
- Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)Pivotal-lookingActive, not recruiting
German CLL Study GroupAcademic, hospital or other
NCT04608318 · 897 participants (planned) · Start Mar 1, 2021 · Primary completion Sep 2027
Drug: Ibrutinib; Venetoclax and 1 more · For: Chronic Lymphoid Leukemia
Sites: Graz, Austria; Innsbruck, Austria; Vienna, Austria · 181 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,999
- neutropenia1,407
- covid-191,094
- febrile neutropenia1,049
- pyrexia1,027
- thrombocytopenia963
- disease progression961
- infusion related reaction882
- pneumonia805
- anaemia737
- infection625
- atrial fibrillation606
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 2 |
| 2012 | 19 |
| 2013 | 122 |
| 2014 | 410 |
| 2015 | 375 |
| 2016 | 689 |
| 2017 | 850 |
| 2018 | 1,074 |
| 2019 | 950 |
| 2020 | 1,195 |
| 2021 | 1,177 |
| 2022 | 2,314 |
| 2023 | 2,103 |
| 2024 | 2,473 |
| 2025 | 1,689 |
| 2026 | 1,487 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Gazyva (Obinutuzumab)
2024 spending
$8.6M
Beneficiaries
210
766 claims
Per beneficiary
$40,972
$199.72 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,888,807 |
| 2021 | $2,264,298 |
| 2022 | $3,974,197 |
| 2023 | $5,744,762 |
| 2024 | $8,604,069 |
Part B: Gazyva (Obinutuzumab) · HCPCS J9301
2024 spending
$184M
Beneficiaries
5,252
26,537 claims
Per beneficiary
$34,943
2024 ASP limit $72.32 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $132,788,036 |
| 2021 | $137,669,767 |
| 2022 | $138,720,200 |
| 2023 | $162,395,517 |
| 2024 | $183,518,022 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
Furie RA, Rovin BH, Garg JP, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
Brown JR, Seymour JF, Jurczak W, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.
Kumar A, Soumerai J, Abramson JS, et al. · Blood 2025 · Clinical Trial, Phase II, Multicenter Study
- Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
Al-Sawaf O, Stumpf J, Zhang C, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Equivalence Trial
- Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. · N Engl J Med 2022 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.
Sharman JP, Egyed M, Jurczak W, et al. · Blood 2025 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.